A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 22 Oct 2015 Post hoc pooled analysis results published in the British Journal of Cancer
- 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.